ADAGIO THERAPEUTICS
Adagio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The companyโs portfolio of antibodies has been optimized using Adimabโs industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. ... Adagioโs portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with thirdparty contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch.
ADAGIO THERAPEUTICS
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2020-01-01
Address:
Waltham, Massachusetts, United States
Country:
United States
Website Url:
http://www.adagiotx.com
Total Employee:
51+
Status:
Active
Contact:
781-819-0080
Email Addresses:
[email protected]
Total Funding:
466 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Wordpress Plugins Mobile Non Scaleable Content Microsoft Exchange Online
Similar Organizations
Click Therapeutics
Click Therapeutics delivers safe and effective digital treatments to patients in need.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
OrbiMed
OrbiMed investment in Series C - Adagio Therapeutics
Population Health Partners
Population Health Partners investment in Series C - Adagio Therapeutics
Adimab
Adimab investment in Series C - Adagio Therapeutics
Mithril Capital Management
Mithril Capital Management investment in Series C - Adagio Therapeutics
GV
GV investment in Series C - Adagio Therapeutics
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Series C - Adagio Therapeutics
Redmile Group
Redmile Group investment in Series C - Adagio Therapeutics
Foresite Capital
Foresite Capital investment in Series C - Adagio Therapeutics
Polaris Partners
Polaris Partners investment in Series C - Adagio Therapeutics
ArrowMark Partners
ArrowMark Partners investment in Series C - Adagio Therapeutics
Key Employee Changes
Date | New article |
---|---|
2021-07-19 | Adagio Therapeutics Appoints David Hering, Global COVID-19 Vaccine Expert, as Chief Operating Officer |
Official Site Inspections
http://www.adagiotx.com Semrush global rank: 3.47 M Semrush visits lastest month: 4.37 K
- Host name: f3.68.7e4b.ip4.static.sl-reverse.com
- IP address: 75.126.104.243
- Location: Dallas United States
- Latitude: 32.9379
- Longitude: -96.8384
- Metro Code: 623
- Timezone: America/Chicago
- Postal: 75244
More informations about "Adagio Therapeutics"
Adagio Therapeutics Announces Dosing of First Patient โฆ
Feb 16, 2021 WALTHAM, Mass.--(BUSINESS WIRE)--Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, today announced the initiation of a ...See details»
EX-99.1 - SEC.gov
Prior to his most recent role at Pfizer, Mr. Hering was president, North America at Pfizer, where he led a 700-person organization across a portfolio of vaccine products for COVID-19 and โฆSee details»
Adagio enters a crowded field - TSI Wealth Network
ADAGIO THERAPEUTICS INC. $27 is a hold. The company (Nasdaq symbol ADGI; Manufacturing sector; Shares outstanding: 108.5 million; Market cap: $2.9 billion; No dividend โฆSee details»
Adagio Announces Results of Annual Meeting of Stockholders and ...
Jul 1, 2022 Marc Elia Named Chair of the Board of DirectorsWALTHAM, Mass., July 01, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage โฆSee details»
Adagio Therapeutics Announces New In Vitro Data Highlighting โฆ
Oct 19, 2021 Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers to support the completion of clinical trials and initial commercial โฆSee details»
Adagio Announces Results of Annual Meeting of Stockholders
Jul 1, 2022 For more information, please visit www.adagiotx.com. Cautionary Note Regarding Forward Looking Statements This press release contains forward-looking statements within โฆSee details»
Adagio Therapeutics Announces ADG20 Development Plans and
Feb 22, 2022 The safety and efficacy of ADG20 have not been established. For more information, please visit www.adagiotx.com. Forward Looking Statements .See details»
Adagio Therapeutics Summarizes ADG20 Neutralizing Activity โฆ
Jan 12, 2022 Recent Publications by Several Independent Laboratories Show ADG20 Has Neutralizing Activity with Potency Comparable to Other Antibodies that Retain Activity Against โฆSee details»
Adagio Therapeutics Initiates Global Clinical Trial of ADG20 as a ...
Apr 13, 2021 WALTHAM, Mass.--(BUSINESS WIRE)--Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize โฆSee details»
Adagiotx.com Antibody-based therapies to address evolving
Organization: Location: Issuer: E6 Valid from: Nov 14 04:21:08 2024 GMT Valid until: Feb 12 04:21:07 2025 GMT Authority: CA:FALSE Keysize: Common Name: E6 ... Domain Name: โฆSee details»
Adagio Therapeutics to Present at the 40th Annual J.P.
Jan 6, 2022 A live webcast will be available in the investor section of the company's website at investors.adagiotx.com and will be archived for 60 days following the presentations. About โฆSee details»
Adagio Therapeutics to Participate in Upcoming Investor โฆ
Sep 6, 2022 A live webcast of the fireside chat will be available in the investor section of the company's website at investors.adagiotx.com and will be archived for 90 days following the โฆSee details»
Adagio Therapeutics Announces $336 Million Series C Financing to ...
Apr 19, 2021 Adagio Therapeutics Announces $336M Series C Financing to Support Rapid Advancement of Novel ADG20 Antibody for Treatment and Prevention of COVID-19See details»
Adagio Therapeutics Reports Second Quarter 2022 Financial โฆ
For more information, please visit www.adagiotx.com. Cautionary Note Regarding Forward Looking Statements This press release contains forward-looking statements within the โฆSee details»
Adagio Therapeutics Appoints David Hering, Global COVID-19
Waltham, MA โ July 19, 2021 โ Adagio Therapeutics, Inc., a biotechnology company developing highly differentiated antibodies to broadly neutralize coronaviruses, today announced that โฆSee details»
Adagio Therapeutics Appoints David Hering, Global COVID-19 โฆ
Jul 19, 2021 Prior to his most recent role at Pfizer, Mr. Hering was president, North America at Pfizer, where he led a 700-person organization across a portfolio of vaccine products in โฆSee details»
Antibody-based therapies to address evolving viral threats | Invivyd
Nov 14, 2024 OUR INVYMABโข PLATFORM. Leveraging state-of-the-art viral surveillance, predictive modeling, and advanced antibody engineering techniques, we are taking a platform โฆSee details»
Adagio Therapeutics Provides Update for ADG20 COVID-19
Nov 15, 2021 September 30, 2021 December 31, 2020 Assets Current assets: Cash and cash equivalents $ 478,269 $ 114,988 Marketable securitiesSee details»
Organization: Invivyd - Cbonds.com
11/04/2024: Invivyd: Item 9.01, Financial Statements And Exhibits: 04/04/2024: Invivyd: On April 4, 2024, The Company Also Posted An Updated Corporate Presentation On Its Website At โฆSee details»
Adagio Therapeutics Announces ADG20 Phase 1 Data and โฆ
May 5, 2021 Preliminary Data from Ongoing Phase 1 Trial in Healthy Volunteers Support ADG20 Safety and Pharmacokinetic Profile and SARS-CoV-2 Neutralizing Activity. Phase 2/3 โฆSee details»